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Role of Fish Oil in Prevention of Cardiovascular Diseases: A Systematic
Review
CHING-YUEN WONG, CHU-PAK LAU, HUNG-FAT TSE
From Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong
Kong SAR
WONG ET AL.: Role of Fish Oil in Prevention of Cardiovascular Diseases: A Systematic Review. Epidemiological
studies have shown that fish oil intake has cardioprotective effects. These benefits are ascribed to the active ingredients
of fish oil, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Experimental and clinical studies have
demonstrated that EPA and DHA exhibit their cardioprotective mechanisms via anti-arrhythmic, anti-atherogenic,
anti-thrombotic and vasoprotective effects. In clinical trials, the clinical benefit of fish oil intake appears to be more
prominent on secondary prevention than primary prevention. Furthermore, the triglyceride-lowering property of fish
oil may be more beneficial for primary prevention in certain high risk patients, such as patients with Type II diabetes
mellitus and metabolic syndrome. Nevertheless, fish oil has also been shown to be associated with worsening of
glycaemic control, and increasing in plasma low-density lipoprotein cholesterol level. Therefore, whether fish oil
supplement has cardioprotective effects in different selected subgroups of high risk subjects remain unclear, and
further randomized controlled trials are required. (J HK Coll Cardiol 2007;15:1-11)
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Introduction
Coronary heart disease (CHD) is an emerging
health problem in Hong Kong and other developed
countries. This rising incidence of CHD is ascribed to a
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'westernized lifestyle' which consists of high-fat diets
and a lack of exercises. Numerous epidemiological
studies have demonstrated a positive correlation
between CHD and the amount of lipid intake, 1,2
especially those rich in saturated fatty acids and transfatty acids which are easily obtained from meat.
On the other hand, Greenland Eskimos have a
low CHD mortality despite a high intake of fat which
contributes to about 40% of their total caloric intake.3-6
Epidemiological studies in the 1970s suggested that this
paradox was due to their high consumption of fish and
fish-eating mammals which are rich in fish oil.7,8 Fish
oil contains abundant very long-chain omega-3
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polyunsaturated fatty acids (n-3 PUFA), which differs
from those saturated fatty acids and trans-fatty acids in
terms of their chemical structures and biochemical
properties. Since then, other epidemiological studies of
the coastal population of Japan and Alaska have also
demonstrated the inverse relationship between n-3
PUFA from fish intake and CHD mortality, 9-13
suggesting the potential benefit of fish oil in the
prevention of CHD.

Omega-3 polyunsaturated fatty acids
Fatty acids can be divided into saturated and
unsaturated fatty acids, distinguished by the absence
and presence of double bond(s) respectively.
Monounsaturated fatty acid contains only 1 double bond
in its long carbon chain, and polyunsaturated fatty acid

contains more than 1 double bond.
There are two families of natural polyunsaturated
fatty acids: the omega-6 (n-6) family and the omega-3
(n-3) family with the final double bond located at 6
carbon and 3 carbon atoms away from the end of the
long carbon chain, respectively (Figure 1). These two
classes of polyunsaturated fatty acid cannot be
interconverted in the human body. The polyunsaturated
fatty acid is considered very long-chain if its carbon
chain contains more than 18 carbon atoms. The n-6
family is derived from linoleic acid, and the n-3 family
is derived from alpha-linolenic acid (ALA). These two
fatty acids are essential fatty acids, i.e. they have to be
ingested from our diets. Dietary sources of n-6 PUFA
include various plant oils such as corn, olive, safflower
and sunflower seed oils, and dietary n-3 PUFA can be

Figure 1. (a) linoleic acid (18:2 n-6); (b) arachidonic acid (20:4 n-6); (c) alpha-linolenic acid (18:3 n-3);
(d) eicosapentaenoic acid (20:5 n-3); (e) docosahexaenoic acid (22:6 n-3). The first number in the ratio denotes the
number of carbon atoms in the long carbon chain, whereas the other one denotes the number of double bonds in the
chain.
2
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found in other plant oils, such as linseed, soy and canola
oils, as well as fatty fish, such as salmon, sardines, trout,
mackerel and herrings. ALA is the only n-3 PUFA of
plant origin. More unsaturated very long-chain n-3
PUFA, such as eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), are abundant in fish oil.
EPA and DHA are the active ingredients of fish
oil which can be synthesized by elongation and
desaturation of ALA in the human body, mainly in the
liver (Figure 2). Nevertheless, the conversion of ALA
to EPA is limited, and the whole body conversion of
ALA to DHA is less than 5% in humans. Furthermore,
their conversion in the body depend on the
concentration of dietary n-6 PUFA and very longchain PUFA intake. 14-18 Both EPA and DHA are
incorporated into phospholipids of all cell membranes,
especially in myocardium, retina and brain. They are
crucial for the regulation of cell metabolism by

influencing the membrane fluidity and ion transports.
EPA also competes with arachidonic acid, which is an
n-6 PUFA, for cyclooxygenases in eicosanoid synthesis
(Figure 2). Eicosanoids derived from arachidonic acid,
such as thromboxane A2 and leukotriene B4, are prothrombotic and pro-inflammatory, whereas those
derived from EPA, such as prostacyclin, thromboxane
A3 and leukotriene B5, are anti-thrombotic and antiinflammatory.19,20 EPA and DHA have been studied in
a wide spectrum of diseases (Table 1), and the ratio
between n-3 PUFA and n-6 PUFA in diets, rather than
the absolute amount of n-3 PUFA, may be more
important for disease prevention. 21, 22 Although the
clinical efficacies of EPA and DHA in the prevention
of cardiovascular diseases remain to be proven, there
are several potential cardioprotective mechanisms,
including anti-arrhythmic, anti-atherogenic, antithrombotic and vasoprotective effects as discussed

Figure 2. Metabolism of n-3 and n-6 PUFA and synthesis of eicosanoids. EPA is converted to DHA by further
desaturation and elongation processes.
J HK Coll Cardiol, Vol 15
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Table 1. Potential spectrum of benefits from n-3 PUFA
• Cardiovascular diseases
• Retinal and brain development, especially during infancy
• Autoimmue diseases, e.g. systemic lupus erythmatosis, rheumatoid arthritis
• Crohn's disease
• Cancers of breast, prostate and colon

below. Furthermore, these effects also appear be shown
a dose-response relationships.

Anti-arrhythmic effect
In the DART trial,23 2033 Welsh men with recent
myocardial infarction (MI) were randomized to receive
at least 2 servings of fatty fish per week or capsules
with 0.5 gram of fish oil daily. There was a significant
29% reduction in both cardiac and total mortality within
4 months compared with the control group. However,
there was no significant reduction in the incidence of
recurrent non-fatal MI. As a result, the anti-arrhythmic
effects of fish oil have been postulated to account for
these beneficial effects by reducing sudden cardiac death
elicited by ventricular arrhythmias.
G I S S I - P r ev e n z i o n e t r i a l , 2 4 t h e l a rg e s t
randomized controlled trial on fish oil provided
further support for the anti-arrhythmic mechanism.
In this study, 11324 patients with post-MI
randomized to receive 1 gram fish oil capsule daily
(containing 850-882 mg of EPA and DHA) had a
significant 20% reduction in cardiovascular mortality,
non-fatal MI and stroke after 3.5 years follow-up.
Subsequent time-course reanalysis showed that the
total mortality was significantly lowered by 41% after
3 months and a significant 53% reduction in sudden
death after 4 months. 25 It is worth to note that the
majority of patients in this trial were already on
aspirin, beta-blockers, angiotensin converting enzyme
inhibitors and/or statins. A further 30% significant
reduction in cardiovascular mortality in this trial
suggests the potency of EPA and DHA in secondary
prevention after MI. 25 Moreover, this group of
patients was Italian who consumed Mediterranean
diet including moderate fish consumption. Therefore,

4

a greater benefit may be conferred to populations with
a 'westernized' lifestyle.
Despite these suggestions of the apparent antiarrthythmic effect of EPA and DHA, the exact cardiac
electrophysiology is still unclear. The incorporation of
EPA and DHA into the membrane phospholipids in
cardiac myocytes can increase the membrane fluidity.
This may also inhibit the conductances of the voltagedependent sodium and L-type calcium ion channels, as
well as the voltage-dependent potassium and transient
outward channels, either as incorporated form or free
circulating form.26,27 These changes in the compositions
of membrane phospholipids may influence the synthesis
of eicosanoids to reduce the vulnerability to develop
ventricular fibrillation during myocardial ischemia and
reperfusion.26,28 Furthermore, EPA and DHA may have
indirect anti-arrhythmic effects through modulation of
autonomic nervous system with increased heart rate
variability and baroreflex sensitivity, and reduced
premature ventricular complexes.27,28

Anti-atherogenic effect
Several mechanisms have been postulated to
account for the potential anti-atherogenic effects of fish
oil, including lowering of plasma triglyceride with a
moderate increase in high-density lipoprotein
cholesterol (HDL-C), anti-inflammatory effect due to
changes in eicosanoid synthesis, and reducing the
expression of cell adhesion molecules.26,29 In contrast
to the anti-arrhythmic effect which can be exerted on a
low dose (smaller than 1g daily), the antiatherogenic
effect requires a higher dose.26
Type II diabetes mellitus (DM) is associated with
hypertriglyceridaemia, low levels of HDL-C and an
abnormal composition of low-density lipoprotein
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cholesterol (LDL-C), so EPA and DHA may be
beneficial to these patients. Nevertheless, the use of EPA
and DHA may result in a poor glycaemic control in
patients with impaired glucose tolerance or DM.30,31
Previous studies have suggested that insulin secretion
might be reduced by the intake of n-3 PUFA due to the
changes in membrane fluidity and responsiveness of
pancreatic islet cells to normal stimuli.32 Furthermore,
the use of EPA and DHA may increase oxidative stress
through lipid peroxidation due to their polyunsaturated
property, which may contribute to the development of
atherosclerosis.33
Table 2 summarizes the clinical trials33-56 on the
effect use of EPA and DHA supplement in patients with
type II DM. Sirtori et al randomized 418 patients with
type II DM to 1.5 g EPA and 1.0 g DHA for the first 2
months and then a total of 1.0 g EPA and 0.7 g DHA for
the subsequent 6 months, and showed a significant 15%
reduction of plasma triglyceride compared with placebo.
Nevertheless, there were no changes in major glycaemic
indexes including fasting blood glucose, haemoglobin
A1c (HbA1c), insulinaemia and oral glucose tolerance.
Furthermore, meta-analysis57 also demonstrated that fish
oil supplementation in patients with type II DM lowered
plasma triglyceride level, and had no statistically
significant effect on glycaemic control. Nevertheless,
the use of higher dose of fish oil in patients with
hypertriglyceridaemia significantly increased LDLC level. There is very limited clinical data on the
effect of EPA and DHA on oxidative stress, and the
results from clinical trials showed inconsistent
results. 33,46,52

Anti-thrombotic effect
Previous studies have shown that fish oil
i m p r oved pla telet function in patie nts wi t h
hypertension or DM. 43,56,58 This effect has been
attributed to EPA which compete with arachidonic
acid in eicosanoid synthesis, causing a decrease in
the thromboxane A2: thromboxane A3 ratio and an
increase in prostacyclin I3. However, while DHA is
not a substrate for cyclooxygenase, evidences have
shown that purified DHA can also reduce platelet
aggregation. 59,60 Woodman et al have suggested that
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highly purified DHA may be even more effective than
EPA for the anti-thrombotic effect. 56 This may be
owing to the replacement of arachidonic acid by DHA
in platelet membrane phospholipids, inhibition of
cyclooxygenases, or direct effects of DHA on platelet
function independent of eicosanoid production.56

Vasoprotective effect
EPA and DHA improve vascular endothelial
function by increasing the availability of nitric oxide.26,27,61
Previous studied have suggested that supplement of
DHA with pure n-3 PUFA, but not EPA, contributed to
the improvement in endothelial function.62 Nevertheless,
there is only very limited clinical data on the effects of
fish oil on vascular endothelial function. 56 Further
studies are required to investigate the effects of fish oil
supplement on vascular endothelial function in different
subgroup of high risk subjects.

Conclusions
In summary, fish oil supplement has been shown
to improve clinical outcomes in post-MI patients,
possibly attributed by its anti-arrhythmic effects.
Furthermore, existing data demonstrated that fish oil
supplement reduced plasma triglyceride level without
significant effect of blood glucose level over short term
usage, which may contribute to an anti-atherogenic
effect. However, the potential cardioprotective effects
of fish oil, including anti-thrombotic and vasoprotective
effects remain unproved. Furthermore, the long term
effects and the optimal dosage of fish oil supplement
remain unclear. Therefore, further randomized
controlled trials will be required to prove the beneficial
effect of fish oil on the prevention of cardiovascular
diseases.
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Table 2. Summary of clinical trials
Study

Duration Participants

Schectman
et al 198834

4 weeks

Borkman et al 3 weeks
198935

Hendra et al
199036

6 weeks

Annuzzi et al
199137

2 weeks

Boberg et al
199238

8 weeks

Connor et al
199339

24 weeks

Westerveld
et al 199340

8 weeks

6

13 participants
with type 2 DM
46% hypertriglyceridaemia,
46% hypertension,
15% CHD
10 participants with
mild type 2 DM,
20% hypertension,
10% CHD
80 participants with
type 2 DM; 70% of
intervention group
had microvascular
complications
compared with 42.5%
in control group,
35% of control group
had CAD compared
with 7.5% in fish oil
group.
8 males with type 2
DM

Interventions

Outcomes
Significant
Insignificant
Low dose: 2.6 g EPA TG ↓24% at low dose and HDL-C, apoA1
+ 1.4 g DHA;
39% at high dose
High dose: 5 g EPA +
2.5 g DHA vs. 12 g
safflower oil
1.8 g EPA +
1.2 g DHA vs.
10 g safflower oil

FBG ↑ 14 % compared
with baseline

TG, LDL-C, HDL-C, TC

1.8 g EPA +
1.2 g DHA vs.
10 g olive oil

TG ↓
FBG ↑ after 3 weeks
Spontaneous platelet
aggregation in whole
blood ↓ after 6 wk
Factor VII ↑

TC, FBG after 6 weeks

1.8 g EPA +
1.2 g DHA vs.
10 g olive oil
1.8 g EPA +
1.2 g DHA vs.
10 g olive oil

TG ↓
LDL-C ↑

FBG, average daily blood
glucose

TG and VLDL-TG ↓ by
27% and 36%
respectively compared
with baseline FBG and
HbA1c ↑ compared with
baseline
Plasminogen inhibitor-1
↑ 21% compared with
baseline
16 participants with 4.1 g EPA +
TG, VLDL-TG and
type 2 DM and
1.9 g DHA vs.
VLDL-C ↓
hypertriglyceridaemia 15 g olive oil
LDL-C ↑
20 participants with Low dose: 0.9 g EPA Platelet-activating
type 2 DM
High dose: 1.8 g EPA factor-induced platelet
vs. 1.6 g olive oil
aggregation ↓ in both
high and low dose groups
LDL-C ↑

14 participants with
type 2 DM
43% hypertension
7% CAD
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LDL-C ↑, FBG, HbA1c

TC, HDL-C

Triglycerides, glycemic
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Table 2. Summary of clinical trials (con't)
Study

Duration Participants

Interventions

McVeigh et al 6 weeks
199341

23 participants with
type 2 DM

1.8 g EPA + 1.2 g
DHA vs. olive oil

McVeigh et al 6 weeks
199442

20 participants with
type 2 DM

1.8 g EPA + 1.2 g
DHA vs. olive oil

Axelrod et al
199443

6 weeks

18 participants with
type 2 DM

1.1 g EPA +
1.5 g DHA vs.
5 g safflower oil

Puhakainen
et al 199544

6 weeks

9 participants with
type 2 DM

Morgan et al
199545

12 weeks

McGrath et al 6 weeks
199646
McManus et al 3 months
199647
Sirtori et al
199748

8 months

J HK Coll Cardiol, Vol 15

Outcomes
Significant
By venous occlusion
plethysmography,
forearm blood flow ↑ by
acetylcholine
Forearm blood flow ↓ by
N c monomethylL-arginine
Large-artery compliance
estimate ↑
Oscillatory compliance
value ↑
TG ↓ by 44 mg/dl
SBP ↓ by 8 mmHg
HbA1c ↓ by 0.56%
TC ↓ by 20 mg/dl

2.16 g EPA + 1.44 g TG, VLDL-TG,
DHA vs. 12 g corn + HDL3-TG ↓ by 16%,
olive oil (6 g each) 23% and 21% respectively
40 participants with Low dose: 2.6 g EPA TG, VLDL-TG,
well controlled type 2 + 2.4 g DHA
VLDL-C ↓,
DM and hyperHigh dose: 5.2 g EPA LDL-C ↑ at week 6
triglyceridaemia
+ 4.8 g DHA vs. 9 or
18 g corn oil
23 participants with 1.8 g EPA + 1.2 g
Thiobarbituric acid
type 2 DM
DHA vs. 10 g olive oil reacting substances ↑ by
32%; vitamin E ↓ by 19%
11 participants with 1.8 g EPA + 1.2 g
TG ↓
well controlled type 2 DHA vs. 35 mg/kg
DM 36% obese
linseed oil
418 participants with 1.5 g EPA + 1.0 g
TG ↓ by 15%
type 2 DM and
DHA for 2 months,
hyperlipidaemia
then 1.0 g EPA +
0.7 g DHA for 6
months vs. 3 g olive
oil for 8 months

April 2007

Insignificant
Forearm blood flow by
GTN

FBG, HDL-C, LDL-C,
collagen-induced
thromboxane A2
production, ADP-induced
platelet aggregation or
TXA2 generation
FBG, HbA1c, body
weight
LDL-C at week 12, TC,
HDL-C, FBG, HbA1c,
weight, BP

TG ↓ by 14%, FBG ↑ by
3.5%, HDL, HbAlc, LDL,
apolipoprotein B
Weight, FBG, insulin
levels, HbA1c, TC,
LDL-C, HDL-C
FBG, HbA1c, insulin, and
oral glucose tolerance
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Table 2. Summary of clinical trials (con't)
Study

Duration Participants

Goh et al
199749

12 weeks

Luo et al
199850

2 months

Patti et al
199951

6 months

Mori et al
199952

8 weeks

Woodman
et al 200253

6 weeks

8

Interventions

Outcomes

Significant
Insignificant
TG ↓ by 43% in low P/S
diet
TG ↓ by 71% in high P/S
diet
LDL-C ↑ by 2.5% in low
P/S diet
LDL-C ↑ by 4.5% in high
P/S diet
12 male participants 1.08 g EPA + 0.72 g TG ↓ by 14%
FBG, insulin, HbA1c, TC,
with type 2 DM, Not DHA VS 6 g
LDL-C, HDL-C
on insulin; 20%
sunflower oil
hypertension; 10%
Hyperlipidaemia
16 hyper2.5 g ω-3 fatty acids
Significant:
triglyceridaemia
for 2 months, then
Small LDL-C ↑ by 10%
type 2 DM
1.7 g ω-3 fatty acids
participants
for 4 months
Insignificant:
VS 3 g olive oil for
Other LDL and VLDL
2 months, then 2 g
distribution and size
olive oil for 4 months
55 participants with Low-fat (30% of
Urinary F2-isoprostanes Urinary F2-isoprostanes
type 2 DM, hyperdaily energy) diet
↓ by 20% by fish diet
↓ by 20% by moderate
triglyceridaemia and/ with daily fish
Urinary F2-isoprostanes exercise
or hypoHDL-Cemia (3.6 g ω-3 fatty acids) correlated with BMI, and
vs. Low-fat diet alone TG at baseline
vs. Moderate exercise
vs. Moderate exercise
with low-fat (30% of
daily energy) diet
with daily fish (3.6 g
ω-3 fatty acids)
51 participants with 4 g EPA vs. 4 g DHA FBG ↑ by 1.40 mmol/L HbA1c, BP, TC, LDL-C,
type 2 DM and drug vs. 4 g olive oil
and 0.98 mmol/L in EPA HDL-C
treatment for
and DHA groups
hypertension
respectively
TG ↓ by 19% and 15% in
EPA and DHA groups
respectively
HDL2-C ↑ by 16% and
12% in EPA and DHA
groups respectively
HDL3-C ↓ by 11% with
EPA
28 participants with 1.4 g EPA + 0.88 g
type 2 DM divided
DHA VS 35 mg/kg
into a low
linseed oil
polyunsaturated/
saturated fat (P/S) and
a high P/S diet group
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Table 2. Summary of clinical trials (con't)
Study

Duration Participants

Petersen et al
200254

8 weeks

Pedersen et al 8 weeks
200355

Outcomes

42 participants with 4 g fish oil
type 2 DM, hypercontaining 2.6 g
triglyceridaemia and EPA+DHA vs. 4 g
low or moderate
corn oil
alcohol intake
Both containing
13.4 mg vit. E
49 participants with 4 g fish oil containing
type 2 DM and
2.6 g EPA+DHA vs.
hypertriglyceridaemia 4 g corn oil

Woodman et al 6 weeks
200356

51 participants with
type 2 DM and drug
treatment for
hypertension

Mori et al
200333

51 participants with
type 2 DM and drug
treatment for
hypertension

6 weeks

Interventions

Significant
TG ↓ 12 times more
HDL2b-C ↑ 0.05 mmol/L
more
HDL2a-C ↓ 66% less

LDL oxidation mean lag
time and mean
propagation time ↓ by
16% and 17%
TG ↓
HDL ↑
4 g EPA VS 4 g DHA Collagen aggregation ↓
vs. 4 g olive oil
by 16.9%
Collagen-stimulated
thromboxane release ↓
by 18.8%
4 g EPA
Urinary F2-isoprostanes
vs. 4 g DHA
↓ by 19% and 20% with
vs. 4 g olive oil
EPA and DHA
respectively

Insignificant
LDL-C, HDL-C, conc. of
small dense LDL
particles

HbA1c, FBG

PAF-stimulated platelet
aggregation, fibrinolytic
function, vascular
function by FMD and
NMD
CRP, IL-6, TNF-α

Abbreviations: CHD= coronary heart disease; CRP=C-reactive protein; DHA=docosahexaenoic acid; DM=diabetes mellitus; EPA=
eicosapentaenoic acid; FMD=flow mediated dilation; FBG=fasting blood glucose; HDL-C=high density lipoprotein-cholesterol; LDL-C=
low density lipoprotein-cholesterol; NMD=nitroglycerin mediated dilation; SBP=systolic blood pressure; TC= total cholesterol; TNF= tumor
necrosis factor; TG=triglyceride
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